RN7SL862P

Across TCGA pan-cancer cohorts, RN7SL862P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RN7SL862P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RN7SL862P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL862P is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

BRCA, KIRC, and HNSC are the cancer types where RN7SL862P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL862P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.257	.001	6	view →
KIRC	Male	All	+0.054	.017	3	view →
HNSC	Male	II,III,IV	+0.134	.006	2	view →
LUSC	All	All	−0.161	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RN7SL862P–BRCA

Open the BRCA breakdown →